118 related articles for article (PubMed ID: 37918903)
1. Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting.
Palmer AJ; Zhao T; Taylor BV; van der Mei I; Campbell JA
J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):401-409. PubMed ID: 37918903
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
4. Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.
Palmer AJ; van der Mei I; Taylor BV; Clarke PM; Simpson S; Ahmad H
Mult Scler; 2020 Apr; 26(4):411-420. PubMed ID: 30806569
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
Si S; Zomer E; Fletcher S; Lee J; Liew D
Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
[TBL] [Abstract][Full Text] [Related]
6. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
7. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
[TBL] [Abstract][Full Text] [Related]
8. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
[TBL] [Abstract][Full Text] [Related]
9. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
11. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
Hutton DW; Tan D; So SK; Brandeau ML
Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.
Mozaffarian D; Liu J; Sy S; Huang Y; Rehm C; Lee Y; Wilde P; Abrahams-Gessel S; de Souza Veiga Jardim T; Gaziano T; Micha R
PLoS Med; 2018 Oct; 15(10):e1002661. PubMed ID: 30278053
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan.
Hoshi SL; Seposo X; Okubo I; Kondo M
Vaccine; 2018 Aug; 36(34):5133-5140. PubMed ID: 30041878
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
Meier G; Gregg M; Poulsen Nautrup B
J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
[TBL] [Abstract][Full Text] [Related]
19. Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price.
Kim H; Goodall S; Liew D
J Med Econ; 2021; 24(1):893-899. PubMed ID: 34259119
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness evaluation of the 45-49 year old health check versus usual care in Australian general practice: A modelling study.
Si S; Moss J; Karnon J; Stocks N
PLoS One; 2018; 13(11):e0207110. PubMed ID: 30412596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
